PatientsVille.com Logo

Urinary and Ciprofloxacin

PatientsVille

Urinary Symptoms and Causes

Urinary incontinence (UI) is loss of bladder control. Symptoms can range from mild leaking to uncontrollable wetting. It can happen to anyone, but it becomes more common with age. Women experience UI twice as often as men.

Most bladder control problems happen when muscles are too weak or too active. If the muscles that keep your bladder closed are weak, you may have accidents when you sneeze, laugh or lift a heavy object. This is stress incontinence. If bladder muscles become too active, you may feel a strong urge to go to the bathroom when you have little urine in your bladder. This is urge incontinence or overactive bladder. There are other causes of incontinence, such as prostate problems and nerve damage.

Treatment depends on the type of problem you have and what best fits your lifestyle. It may include simple exercises, medicines, special devices or procedures prescribed by your doctor, or surgery.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for urinary

urinary treatment research studies

Ciprofloxacin clinical trials, surveys and public health registries


Find Drug Side Effect reports



Ciprofloxacin Side Effects

Arthralgia (550)
Pain In Extremity (389)
Tendonitis (280)
Diarrhoea (274)
Pyrexia (260)
Renal Failure Acute (240)
Tendon Pain (237)
Dizziness (236)
Headache (234)
Anxiety (233)
Myalgia (229)
Nausea (225)
Pain (225)
Paraesthesia (219)
Insomnia (208)
Fatigue (204)
Rash (202)
Gait Disturbance (196)
Confusional State (187)
Tendon Rupture (174)
Asthenia (173)
Hypoaesthesia (168)
Pruritus (165)
Vomiting (163)
Dyspnoea (159)
Oedema Peripheral (147)
Muscular Weakness (140)
Muscle Spasms (132)
Abdominal Pain (129)
Neuropathy Peripheral (128)
Back Pain (127)
Burning Sensation (126)
International Normalised Ratio Increased (126)
Erythema (124)
Tendon Disorder (121)
Malaise (113)
Depression (112)
Feeling Abnormal (110)
Urticaria (109)
Musculoskeletal Pain (107)
Chest Pain (105)
Joint Swelling (104)
Convulsion (99)
Condition Aggravated (98)
Sepsis (94)
Agitation (94)
Tinnitus (93)
Abasia (93)
Palpitations (93)
Urinary Tract Infection (89)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I have been taking ciprofloxacina for an stomacal infection. It has worked well, I feel much better but I have experienced dizziness (a lot of dizziness).

side effects of ciprofloxacine on strocke patients

After a couple of days on Cipro, I started to have hallucinations. I remembered yellow dots and other figures. So bad that I had to change meds.

Can claritine cause urinary problems?

DOES CIPROFLOXACI CAUSE DEATH OR IT SOME RELATED ISSNESS

Effects of ciprofloxacin on CVA patients

Elderly patient with IT and massive mastoid sinusitis being treated with vancomycin/cipro IV duo. Side effects???

Heyyy

Hi few days ago i went to my gp with urine burning pain leftside of belly bit blood in urine and now i have small swelling to my belly near belly button it feels sore and hurts when i touch it can anyone out there plz help me

Hi, I have had A UTI for feels like month now I was put on Cipro did not work now I am on Baxtrum, almost done with it but I am not getting better I feel worse now with aching in my left side. Whta is going on, I just feel not myself either. should I

48 years of age. I was diagnosed with urinary tract infection. Had one dose of monuril 3 gr. After 7 hours developed skin rash on the back, arms and neck, generally swelling of the face, specially below the eyes, Had oral antihistamine and went to

'Foreign proteins that gain access to the body through cuts and scrapes, through the digestive or circulatory systems, or through the urinary and reproductive systems are called ____.' Answer a) immunoglobulins

42 y.o. female, no medical hx. of urinary incontinence until the use of Mucinex D 1200mg po bid. Resolved after med. being discontinued.

58 year old female patient was prescribed cipro xr 500 twice a day for urinary tract infection. on 4th day, patient developed ithcy rashes. on 6thday, patient experienced low backpain and abdominal pain that felt like arthritic pain.&nb

After being diagnosed with urinary tract infection, had one dose of monuril 3 gr. 7 hours later developed skin rash in all upper body and severe swelling of the face, particularly round the eyes. I had 2 pills of celesemine. In the morning symtoms ha

After taking vistaril 25mh capsules i suffered from urinary retention. So bad I had to be hospitalized. I previously have been treated for an enlarged prostate.

Been on Flomaxtra for 2 months with the following affects. Urinary flow improved immediately but ejaculations ceased totally. Known as retro ejaculation. Penis became inflammed around the head and under the foreskin, Posthitis? but goes away when tab

Blurred vision, joint pain torn miniscus both knees, hot flashes, feeling cold, urinary tract infections seven in one year, some othr mild infections, GI problems, multiple

Can claritine cause urinary problems?

Could not urinate or have bowl movement for two days. By massaging my abdomin I was able to urinate(half hour). Developed urinary tract infection. Lost 20 pounds in two weeks.Have never been suicidal in my life. After taking cymba

Urinary Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension
Condition: Otitis Externa
Interventions: Drug: Cipro HC;   Drug: Ciprofloxacin HCl and Hydrocortisone
Outcome Measures: Cure (reduced pain, swelling and otorrhea);   Identification of possible side effects
2 Recruiting Ciprofloxacin for Prevention of BK Infection
Condition: BK Virus Infection
Interventions: Drug: Ciprofloxacin;   Drug: placebo
Outcome Measures: BK infection at 6 months post-transplant;   Incidence of urinary tract infections as defined by a midstream urine sample containing 10^4 or more colony-forming units per mL;   Incidence of bacteremic infections at 6 months. Incidence of bacteremia as defined by a single positive blood culture that was not thought to be contaminated.;   Incidence of quinolone-resistant bacterial infections;   Incidence of clostridium difficile infection;   Serious adverse events;   Time to BK infection;   Proportion of patients developing BK infection at 1 year;   First and peak plasma viral loads;   Incidence of acute rejection at 1 year;   Incidence and severity of BK nephropathy, as defined by positive staining of histopathological specimen, at 1 year
3 Recruiting Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Condition: Bronchiectasis
Interventions: Drug: Ciprofloxacin: administered for 28 days on / 28 days off;   Drug: Placebo: administered for 28 days on / 28 days off;   Drug: Ciprofloxacin: administered for 14 days on / 14 days off;   Drug: Placebo: administered for 14 days on / 14 days off
Outcome Measures: Time to first exacerbation;   Mean number of exacerbations per patient per 48 weeks;   Pathogens present at baseline and eradicated at 48 weeks;   Quality of Life: Changes of Saint George's Respiratory;   New pathogens at 48 weeks, not present at baseline;   Changes of Forced Expiratory Volume in 1 second from baseline;   Number of participants with Adverse events as a measure of
4 Recruiting Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention
Condition: Adverse Reaction to Other Drugs and Medicines
Interventions: Drug: Norfloxacin;   Drug: Ciprofloxacin
Outcome Measures: The prevention rate of spontaneous bacterial peritonitis (SBP);   1 year mortality;   Incidence of infectious event other than SBP;   Hepatorenal syndrome;   Hepatic encephalopathy;   Adverse event of drugs
5 Recruiting Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Condition: Bronchiectasis
Interventions: Drug: Ciprofloxacin DPI (BAYQ3939);   Drug: Placebo
Outcome Measures: Time to first exacerbation;   Mean number of exacerbations per patient per 48 weeks;   Pathogens present at baseline and eradicated at 48 weeks;   Changes of Saint George's Respiratory Questionnaire score from baseline to 48 weeks;   New pathogens at 48 weeks, not present at baseline;   Changes of Forced expiratory volume in 1 second from baseline to 48 weeks;   Number of participants with Adverse events as a measure of safety and tolerability
6 Recruiting Population Pharmacokinetics of Anti-infectious Drugs in Children
Conditions: Pediatrics;   Ceftazidime;   Ciprofloxacin;   Voriconazole
Interventions: Drug: Ceftazidime;   Drug: Ciprofloxacin;   Drug: Voriconazole
Outcome Measures: Population pharmacokinetic parameters and factors explaining variability;   Covariability factors explaining the variability (age, biological data, pharmacokinetics factors, associated treatments...)
7 Recruiting Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes
Condition: Otitis Media in Patients With Tympanostomy Tubes.
Interventions: Drug: Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension;   Drug: CIPRODEX® (Ciprofloxacin 0.3%/dexamethasone 0.1%);   Drug: Placebo Sterile Otic Suspension
Outcome Measures: Clinical Success;   Cessation of Otorrhea
8 Unknown  TINN Pharmacokinetics (PK) Study Treat Infections iN Neonates
Condition: Pharmacokinetics of Ciprofloxacin in Neonates
Intervention: Procedure: Collection of biological samples
Outcome Measures: Ciprofloxacin plasma concentration and population pharmacokinetic (PK) parameters;   PK variables;   Tolerability;   Safety;   Clinical/microbiological outcomes
9 Not yet recruiting Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects
Conditions: Healthy Volunteers;   Non-smokers
Interventions: Drug: Pracinostat;   Drug: Itraconazole;   Drug: Ciprofloxacin
Outcome Measures: Peak plasma concentration Cmax in healthy nonsmoking subjects given a single-dose of pracinostat;   Number of participants with Adverse Events as a measure of safety and tolerability of single-dose pracinostat when administered with itraconazole or with Ciprofloxacin in healthy nonsmoking adult subjects.;   Peak plasma PK concentration Area Under the Curve (AUC)AUC 0-t, AUC 0-inf in healthy nonsmoking subjects given a single dose of pracinostat
10 Recruiting A Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin in the Treatment of Plague in Humans
Condition: Plague
Interventions: Drug: Ciprofloxacin;   Drug: doxyxcycline
Outcome Measures: all cause mortality;   time to defervesence;   antimicrobial associated adverse events
11 Recruiting Efficacy Study of Prophylaxis With Fosfomycin Versus Ciprofloxacin Prior Prostate Biopsy
Condition: Urinary Tract Infections
Interventions: Drug: Fosfomycin 3 g;   Drug: Ciprofloxacin 500 mg
Outcome Measures: Bacteriuria;   Urinary Tract Infection;   Sepsis;   Pathogens present in urine and antimicrobial resistance;   Bacteremia;   Hematuria;   Hemospermia;   Rectal bleeding;   Urinary retention;   Difficulty for miction;   Genitourinary infections associated to fever (>38ºC);   Number of participants with adverse events
12 Recruiting A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa
Condition: Otitis Externa
Interventions: Drug: Ciprofloxacin/Dexamethasone;   Drug: Ciprodex (R);   Drug: Placebo
Outcome Measures: Clinical Success;   Resolution of Symptoms
13 Recruiting Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis
Condition: Non Cystic Fibrosis Bronchiectasis
Intervention: Drug: Ciprofloxacin
Outcome Measures: Time to first exacerbation;   Number of exacerbations
14 Unknown  Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases
Condition: Febrile Neutropenia
Interventions: Drug: Ciprofloxacin;   Drug: cefepime
Outcome Measures: Treatment efficacy;   Toxicity
15 Recruiting Antibiotics and Hydroxychloroquine in Crohn's
Condition: Crohn's Disease
Interventions: Drug: Ciprofloxacin;   Drug: Doxycycline;   Drug: Hydroxychloroquine;   Drug: Budesonide
Outcome Measures: • Remission, defined as Crohn's Disease activity index (CDAI) <150 at 10 weeks without addition of any other medication or treatment for the Crohn's Disease.;   • Remission, defined as CDAI ≤150 maintained through to 24 weeks;   • Remission, defined as CDAI ≤150 maintained through to 52 weeks;   • Remission defined as CDAI <150 at 4 weeks;   • Response defined as a fall in CDAI by >70 points at 4 weeks and 10 weeks;   • Markers of cost (days admitted to hospital, days unable to carry out normal daily activities, need for surgery);   • Quality of life at 4 weeks, at 10 weeks, or Early Withdrawal;   • Patient global assessment of symptom severity by 10 cm visual analogue score at 4 weeks, at 10 weeks, or Early Withdrawal;   • Adverse Events and possible drug-related side effects: nausea, diarrhoea, mood disturbance, sleep disturbance - will all be assessed at each visit;   • Fall in Faecal Calprotectin
16 Recruiting Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea
Condition: Traveler's Diarrhea
Interventions: Drug: Rifamycin SV MMX;   Drug: Ciprofloxacin
Outcome Measures: Time to Last Unformed Stool (TLUS);   Clinical cure
17 Recruiting Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis
Conditions: SBP;   Liver Cirrhosis
Interventions: Drug: Cefotaxime;   Drug: Ceftriaxone;   Drug: Ciprofloxacin
Outcome Measures: Infection resolution rates within 5 days of treatment;   Infection resolution rates within 5 days;   Mortality & recurrence rates within 1 month
18 Recruiting BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent
Conditions: HIV;   Salivary Gland Disease;   Benign Lymphoepithelial Lesion
Interventions: Drug: Ciprofloxacin;   Drug: Placebo
Outcome Measures: (BK) Virus replication and shedding;   Salivary function
19 Recruiting Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis
Conditions: Urinary Tract Infections;   Acute Pyelonephritis
Interventions: Drug: Finafloxacin 800 mg i.v. once daily;   Drug: Finafloxacin placebo i.v. once daily;   Drug: Finafloxacin 800 mg tablets (as four 200 mg tablets) once daily;   Drug: Finafloxacin placebo tablets (as four tablets) once daily;   Drug: Ciprofloxacin 400 mg i.v. two times daily;   Drug: Ciprofloxacin placebo i.v. two times daily;   Drug: Ciprofloxacin 500 mg oral (as two 250 mg capsules) two times daily;   Drug: Ciprofloxacin placebo oral (as two capsules each) two times daily
Outcome Measures: Clinical and microbiological response of patients with cUTI or pyelonephritis.;   The clinical and microbiological response at the On Therapy (OT) visit (Day 3).;   The clinical and microbiological response at the End of Therapy (EoT) visit (Day 10).;   The clinical and microbiological response at the End of Study (EoS) visit (Day 24).;   The safety and tolerability of multiple doses of finafloxacin of both 5 days and 10 days of treatment with finafloxacin (i.v. and oral) in subjects with cUTI, compared to 10 days of Ciprofloxacin (i.v. and oral).;   The predictive capacity of PK/PD data of both 5 days and 10 days of treatment with finafloxacin (i.v. and oral) in subjects with cUTI, using 10 days of Ciprofloxacin (i.v. and oral) as reference on clinical outcomes (EMA guidance).
20 Recruiting Antibiotic Prophylaxis in Laparoscopic Cholecystectomy
Condition: Cholelithiasis
Interventions: Drug: Ciprofloxacin;   Drug: Ampicillin-sulbactam;   Drug: Placebo
Outcome Measures: Surgical site infection;   Extra-abdominal infections;   Adverse events.;   Quality of life